Esperion hits a homer with new cholesterol data

Stock surged on news that patients taking a statin and a drug combination including its bempedoic acid had a 64% reduction in bad cholesterol levels.

By Jacob Bell • Aug. 8, 2017

Investors breathe life into FibroGen after positive lung data

Shares of the biotech skyrocketed on news its lung drug beat out a placebo in a mid-stage study. 

By Lisa LaMotta • Aug. 8, 2017

Explore the Trendline➔

Neuroscience drug development

Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

By BioPharma Dive staff

Zynerba shares up in smoke after trial failure

Shares in the biotech fell sharply after it announced negative topline results for its lead product in a clinical trial. 

By Lisa LaMotta • Aug. 7, 2017

MyoKardia seeks accelerated development for heart drug

Positive findings from a small study have prompted the biotech to seek a more aggressive clinical pathway for its genetic heart disease drug. 

By Suzanne Elvidge • Aug. 7, 2017

Lilly's turn to pain gathers momentum

Positive data for the drugmaker's other migraine drug lasmiditan adds another late-stage success to an emerging portfolio of new treatments for pain.

By Ned Pagliarulo • Aug. 7, 2017

Placebo response dulls otherwise shiny results for Gemphire drug

A higher than expected response in the control group of the cholesterol study pushed down shares, despite a positive outcome. 

By Jacob Bell • Aug. 7, 2017

Prescribed Reading: More portfolios reshuffled

Restructuring continued throughout the industry, as more companies attempt to cut costs or excess programs. Meanwhile, the FDA kept up its rapid pace of drug approvals.

By Lisa LaMotta • Aug. 4, 2017

So far, so good for Spark in hemophilia A

Three patients dosed with SPK-8011 have demonstrated improved Factor VIII levels and no serious adverse effects.

By Jacob Bell • Aug. 3, 2017

Cytokinetics inches forward with heart failure program

Amgen and the smaller biotech have been developing omecamtiv mercabil since 2006, pushing through a clinical setback and dimming commercial prospects for the class. 

By Ned Pagliarulo • Aug. 2, 2017

Theravance downplays mixed data in GI study

In a Phase 2 study, Theravance's velusetrag turned up statistically significant results for one dose, but failed in others. 

By Lisa LaMotta • Aug. 2, 2017

23andMe, Lundbeck unveil mega investigation of genetics' role in depression

Enrollment has already begun for the 25,000-person investigation.

By Jacob Bell • Aug. 2, 2017

Bristol-Myers, Clovis ink industry's latest PARP deal

The companies plan to investigate the combination of Opdivo and Rubraca as a treatment for various cancers.

By Jacob Bell • Aug. 1, 2017

Unfazed by competition, Allergan sees room at CGRP table

Allergan believes it can break into the emerging CGRP migraine market, even as it lags behind other drugmakers' rival products.

By Ned Pagliarulo • July 28, 2017

Prescribed Reading: Pharma marked by restructuring and failures

A week of earnings announcements emphasized changes in portfolios against the backdrop of a major pipeline failure. 

By Lisa LaMotta • July 28, 2017

Bristol shrugs off comparisons to MYSTIC

The big pharma was faced with an onslaught of questions regarding the potential of its own PD-1/CTLA4 combination after AstraZeneca's failure.

By Lisa LaMotta • July 28, 2017

Vertex set up for CF monopoly due to data, contracts

The rollout of further data for its triple combination cystic fibrosis treatments, as well as agreements with payers, could allow the biotech to wipe out competition.

By Lisa LaMotta • July 27, 2017

Quark wins in Phase 2, raising the stakes for RNAi

The company is trying to best Alnylam in being the first to secure FDA approval for an RNAi therapy.

By Jacob Bell • July 27, 2017

MYSTIC flop a major blow to AstraZeneca's I/O hopes

Much-anticipated results from the Phase 3 lung cancer study showed a combination of Imfinzi and tremelimumab failed to deliver a progression-free survival benefit.

By Ned Pagliarulo • July 27, 2017

Tetraphase gains on strong antibiotic results

Shares of the biotech jumped on positive late-stage results, ahead of regulatory filings for the company's antibiotic.

By Lisa LaMotta • July 26, 2017

J&J reports positive results for HIV regimen

Patients taking a once-daily tablet comprised of darunavir and a regimen of Gilead drugs demonstrated low virologic rebound rates and high virologic suppression.

By Jacob Bell • July 25, 2017

Genocea readies Phase 3 for herpes drug

Genocea's Phase 2b immunotherapy data could be a shot in the arm for treatment of recurrent genital herpes.

By Suzanne Elvidge • July 25, 2017

Lilly maps out new approach to cancer R&D

Setting a new bar for its research efforts, the Indianapolis drugmaker will seek to out-license six assets while funneling R&D dollars toward priority projects.

By Ned Pagliarulo • July 25, 2017

Keytruda failure another setback for PD-1/L1 class

Merck's flagship immunotherapy didn't significantly improve overall survival for some head and neck cancer patients — adding to a string of recent setbacks for the anti-PD-1 class.

By Jacob Bell • July 25, 2017

Gilead's combo shows no resistance in HIV

As hepatitis C revenues fall, Gilead is leaning on its HIV franchise, which has been showing strong data. 

By Suzanne Elvidge • July 25, 2017

Bayer misses in mid-stage mesothelioma trial

The drug failed in a Phase 2 study as a treatment for patients with asbestos-linked cancer. Development will continue for other tumor types, however. 

By Suzanne Elvidge • July 24, 2017